This site is intended for healthcare professionals

Novartis Kisqali reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients.

Read time: 2 mins
Last updated:28th Jun 2021
Published:3rd Jun 2021
Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with fulvestrant in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer. The exploratory analysis of OS after an additional 16.9 months of follow-up of the Phase III MONALEESA-3 trial evaluated Kisqali plus fulvestrant as first- or second-line treatment compared to fulvestrant alone in postmenopausal women with HR+/HER2- metastatic breast cancer.
Condition: Breast Cancer HER2-
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest